How McMinn was paid
$3.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Rachel McMinnFounder and Chief Executive Officer | $618,800 | $371,280 | $385,746 | $1,826,570 | $7,157 | $3,209,553 |
| Christine MikailPresident and Chief Financial Officer | $556,000 | $305,800 | $327,642 | $1,552,754 | $12,262 | $2,754,458 |
| Julie JordanChief Medical Officer | $496,800 | $198,720 | $135,576 | $640,392 | $819 | $1,472,307 |
What changed and why
- $3.2MCEO total compensation decreased to $3,209,553 in 2025 from $3,464,815 in 2024.
- Annual discretionary bonuses for services performed were paid early in the following fiscal year.
- Long-term incentives were provided through grants of stock options and restricted stock units.
- Performance share units were granted to key executives tied to clinical development goals.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.